2022-05-09 | NDAQ:HEAR | Press Release | Turtle Beach Corporation

2022-05-10 | NDAQ: INMB | Press release | INmune Bio Inc.

XPro™ enhances remyelination in a Cuprizone model of multiple sclerosis (MS) by improving macrophage phagocytosis (removing) myelin debris.

The data will be presented on May 10, 2022, during the Best Abstract Presentations session.

Presentation can be viewed here.

Boca Raton, Florida, May 10, 2022 (The Globe Newswire) – menMona Bio . company (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing therapies that harness a patient’s innate immune system to fight disease, is pleased to announce that Professor Leslie Probert, Ph. Immunology at the Hellenic Pasteur Institute in Athens, Greece will present data on the effects of tumor necrosis factor (TNF) in MS in 3research and development The European Conference on Neuroinflammation concludes in London today.

Professor Robert has been researching the role of TNF in promoting demyelination (myelin destruction) for more than a decade.

Myelin is a critical component of normal central nervous system function. The myelin sheath, which is produced by oligodendrocytes, is critical for normal nerve function. When the myelin sheath is damaged, neurons cannot transmit signals efficiently, and if the damage continues, the cells undergo neurodegeneration and die. Demyelination is a common feature of many neurodegenerative diseases. A decade ago, Professor Robert’s lab showed that in rodent models of MS, XProTM promoted remyelination (myelin repair) in the white matter while currently approved non-selective TNF inhibitors promote demyelination. Her lab is working to understand why soluble TNF causes demyelination and to identify treatments that promote remyelination.

In the presence of neuroinflammation, dysfunctional microglia promote neuronal death, synaptic impairment, and demyelination. Data presented today shows that XProTM It also promotes remyelination within the brain’s gray matter by stimulating the brain’s natural repair mechanisms. Neutralization of soluble TNF with XProTM Activates pro-glial and astroglial responses to cleanse (phagocytize) degraded myelin and promote remyelination in cortical areas. This data is presented in detail here.

Professor Probert of the Hellenic Pasteur Institute said: “This work underscores the importance of the function of normal microglia in promoting remyelination.” By eliminating soluble TNF, glial autophagy returns, myelin debris is removed, and oligodendrocytes can remodel damaged axons. ”

XPro’s abilityTM To promote remyelination in patients who received 12 months of XProTM for the treatment of Alzheimer’s disease in the recently concluded successful phase 1 trial. Remyelination is measured using radiographic density tensor imaging (RDt), one of the MRI analyzes of new white matter measured in patients by INmune Bio’s imaging partner, IMEKA. In patients receiving a dose of 1 mg/kg/week, remyelination is detected at 3 months and persists for at least 12 months.

“One of the reasons why so few understand that demyelination is part of degenerative diseases like Alzheimer’s is that it has been difficult to measure in patients,” said CJ Barnum PhD, vice president of central nervous system development for INmune Bio. We can see and quantify the demyelination and remyelination in patients with neurodegenerative disease. The time and experience of more treated patients will determine whether XPro’s ability to promote remyelination in diseases such as ADi and MS translates into measurable clinical benefits.”

About XPro™:

XPro1595™ (XPro™) is a next-generation tumor necrosis factor (TNF) inhibitor that acts differently from currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF) without affecting membrane TNF (tmTNF) or TNF receptors. XPro™ can have significant beneficial effects in Alzheimer’s patients by reducing neuroinflammation. For more information on the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neural connectivity, visit this section of the INmune Bio website.

on INmune Bio . company

INmuneBiography,inc. is a public biotechnology company (NASDAQ: INMB), focused on developing treatments that target the innate immune system to fight disease. INmune Bio contains two product platforms under clinical trials: The TNF-negative TNF (DN-TNF) product platform uses dominant-negative technology to selectively neutralize soluble TNF, a major driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are under clinical trials to determine if they can treat cancer (INB03™), mild Alzheimer’s disease, mild cognitive impairment, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ that has been developed to prime a patient’s natural killer cells to eliminate minimal residual disease in cancer patients. INmune Bio product platforms use a meticulous medical approach to treat a wide range of leukemias, malignancies and chronic infections. To learn more, please visit www.inmunebio.com.

forward-looking statements

Clinical trials are still in their early stages and there is no guarantee that any definitive result will be achieved. Any statements in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements in this press release that do not describe historical facts may constitute introductory statements – statements Forward-looking This term is also defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances could differ materially from those shown in the forward-looking statements due to these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to begin clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there can be no guarantee that they will be approved by the FDA or any regulatory body or that no specific results will be achieved. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding the Company’s ability to produce more drugs for clinical trials; Availability of significant additional funding for the Company to continue its operations, conduct research and development, clinical studies and market products in the future; and the company’s business, research, product development, regulatory approval, and marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the company’s filings with the Securities and Exchange Commission, including the company’s annual report on Form 10-K, the company’s quarterly reports on Form 10-Q and the company’s current reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this statement.

INmune Vital Connection:

David Moss, Chief Financial Officer

(858) 964-3720

info@inmunenbio.com

Investor contact:

Jason Nelson

Core IR

(516) 842-9614 × 823


basic logo

2022-05-10 12:00:42

Leave a Comment

Your email address will not be published.